Ligand to Participate in Four Upcoming Investor Conferences
March 12 2019 - 4:01PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announces that company executives are scheduled to participate in
the following upcoming investor conferences:
- Barclays Global Healthcare Conference
in Miami. Presentation takes place on Wednesday, March 13, 2019 at
9:00 a.m. Eastern time (6:00 a.m. Pacific time). John Higgins, CEO
will attend for Ligand.
- 31st Annual Roth Conference in Laguna
Niguel, California. Presentation takes place on Monday, March 18,
2019 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Matt
Foehr, COO and Matt Korenberg, CFO will attend for Ligand.
- H.C. Wainwright Global Life Sciences
Conference in London. Conference takes place on Tuesday, April 9,
2019. John Higgins, CEO will attend for Ligand.
- 16th Annual Craig-Hallum Institutional
Investor Conference in Minneapolis. Conference takes place on
Wednesday, May 29, 2019 with one-on-one meetings only. John
Higgins, CEO, Matt Foehr, COO and Matt Korenberg, CFO will attend
for Ligand.
A live webcast of the Barclays and Roth conference presentations
will be available on Ligand’s website at www.ligand.com. A replay
of the presentations will be archived on the website for 30
days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
Captisol® platform technology is a patent-protected, chemically
modified cyclodextrin with a structure designed to optimize the
solubility and stability of drugs. OmniAb® is a patent-protected
transgenic animal platform used in the discovery of fully human
mono-and bispecific therapeutic antibodies. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Novartis,
Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter
International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190312005650/en/
Ligand Pharmaceuticals IncorporatedTodd
Pettingillinvestors@ligand.com(858) 550-7893@Ligand_LGND
LHABruce Vossbvoss@lhai.com(310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Sep 2023 to Sep 2024